



PTO/SB/08A/B (09-06)

Approved for use through 03/31/2007. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet	1	of	2	Application Number	10/764,140-Conf. #6085
				Filing Date	January 22, 2004
				First Named Inventor	Jin-An Jiao
				Art Unit	1647
				Examiner Name	C. M. Borgeest
				Attorney Docket Number	TNA-005.05

Complete If Known

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			

FOREIGN PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)			

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language translation is attached.

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.		
CB	CA	Bernhard, Gordon, R. et al., "Efficacy and Safety of Recombinant Human Activated Protein C for Severe Sepsis," The New England Journal of Medicine 344:699-709 (2001)		
CB	CB	Bernhard, Gordon, R. et al., "Severe Sepsis - A New Treatment with Both Anticoagulant and Antiinflammatory Properties," The New England Journal of Medicine 344:759-762 (2001)		
CB	CC	Bird et al., "Single-Chain Antigen-Binding Proteins," Science 242(4877):423-6 (1988)		
CB	CD	Bokarewa et al., "Intra-articular tissue factor/factor VII complex induces chronic arthritis," Inflamm Res. 51(9):471-7 (2002)		
CB	CE	Busso et al., "Role of the Tissue Factor Pathway in Synovial Inflammation," Arthritis Rheum 48(3):651-9 (2003)		
CB	CF	Furmanski-Kazmierczak et al., "Studies of Thrombin-induced Proteoglycan Release in the Degradation of Human and Bovine Cartilage," J. Clin. Invest. 94:472-480 (1994)		
CB	CG	Huston et al., "Protein engineering of antibody binding sites: Recovery of specific activity in an anti-digoxin single-chain Fv analogue produced in <i>Escherichia coli</i> ," Proc. Natl. Acad. Sci. USA 85:5879-5883 (1988)		
CB	CH	Jones et al., "Replacing the complementarity-determining regions in a human antibody with those from a mouse," Nature 321:522-525 (1986)		
CB	CI	Junghans et al., "Pharmacokinetics and bioactivity of 1, 4, 7, 10-tetra-azacylododecane off, N", N"-tetraacetic acid (DOTA)-bismuth-conjugated anti-Tac antibody for alpha-emitter (212Bi) therapy," Cancer Research 53(23):5683-9 (1993)		
CB	CJ	Kincaid-Smith, Priscilla, "Participation of intravascular coagulation in the pathogenesis of glomerular and vascular lesions," Kidney International 7:242-253 (1975)		
CB	CK	Kozbor et al., "The production of monoclonal antibodies from human lymphocytes," Immunology Today, 4:72-79 (1983)		
CB	CL	Marty et al., "Amelioration of collagen-induced arthritis by thrombin inhibition," Journal of Clin. Invest. 107(5):631-640 (2001)		

Examiner Signature	Christina Borgeest	Date Considered	8/2/07
-----------------------	--------------------	--------------------	--------

Substitute for form 1449/PTO		Complete if Known	
		Application Number	10/764,140-Conf. #6085
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Filing Date	January 22, 2004
		First Named Inventor	Jin-An Jiao
		Art Unit	1647
		Examiner Name	C. M. Borgeest
		Attorney Docket Number	TNA-005.05
Sheet	2	of	2

CB	CM	Mechtcheriakova et al., "Specificity, diversity, and convergence in VEGF and TNF- α signaling events leading to tissue factor up-regulation via EGR-1 in endothelial cells," The FASEB Journal 15:230-242 (2001)	
CB	CN	Minnema et al., "Recombinant human antrithrombin III improves survival and attenuates inflammatory responses in baboons lethally challenged with <i>Escherichia coli</i> ," Blood 95(4):1117-1123 (2000)	
CB	CO	More et al., "Immunohistochemical study of tissue factor expression in normal intestine and idiopathic inflammatory bowel disease," J. Clin. Pathol. 46:703-708 (1993)	
CB	CP	Morris et al., "Thrombin in inflammation and healing: relevance to rheumatoid arthritis," Annals of the Rheumatic Diseases 53:72-79 (1994)	
CB	CQ	Morrison, Sherie, "Transfectomas Provide Novel Chimeric Antibodies," Science 229:1202-1207 (1985)	
CB	CR	Nakano et al., "Characteristics of the protease activity in synovial fluid from patients with rheumatoid arthritis and osteoarthritis," Clinical and Experimental Rheumatology 17:161-170 (1999)	
CB	CS	Oi, V.T. et al., "Chimeric Antibodies," BioTechniques, 4(3):214-221 (1986)	
CB	CT	Olsson and Kaplan, "Human-Human Monoclonal Antibody-Producing Hybridomas: Technical Aspects," Methods in Enzymology 92:3-16 (1983)	
CB	CU	Osterud et al., "Induction of Tissue Factor Expression in Whole Blood: Lack of Evidence for the Presence of Tissue Factor Expression in Granulocytes," Thromb Haemost 83:861-7 (2000)	
CB	CV	Segal et al., "Tissue Factor Activity in Patients with Systemic Lupus Erythematosus: Association with Disease Activity," The Journal of Rheumatology 27:2827-2832 (2000)	
CB	CW	Schopf et al., "Enhanced procoagulant activity of mononuclear leukocytes in patients with atopic dermatitis and psoriasis," Arch Dermatol Res, 285:305-309 (1993)	
CB	CX	Shen et al., "Vascular Endothelial Growth Factor KDR Receptor Signaling Potentiates Tumor Necrosis Factor-induced Tissue Factor Expression in Endothelial Cells," The Journal of Biological Chemistry 276(7):5281-5286 (2001)	
CB	CY	Varisco et al., "Effect of thrombin inhibition on synovial inflammation in antigen induced arthritis," Annals of Rheumatic Diseases 59:781-787 (2000)	
CB	CZ	Wakefield et al., "Immunohistochemical study of vascular injury in acute multiple sclerosis," J. Clin. Pathol. 47:129-133 (1994)	
CB	CA1	Webber et al., "Preparation and Characterization of a Disulfide-Stabilized Fv Fragment of the Anti-Tac Antibody: Comparison with its Single-Chain Analog," Molecular Immunology 32(4):249-258 (1995)	
CB	CB1	Weinberg et al., "Extravascular Fibrin Formation and Dissolution in Synovial Tissue of Patients with Osteoarthritis and Rheumatoid Arthritis," Arthritis and Rheumatism 34(8):996-1005 (1991)	
CB	CC1	Welty-Wolf et al., "Coagulation Blockade Prevents Sepsis-induced Respiratory and Renal Failure in Baboons," American Journal of Respiratory and Critical Care Medicine 164:1988-1996 (2001)	
CB	CD1	Yamashita et al., "Tissue Factor Expression Is a Clinical Indicator of Lymphatic Metastasis and Poor Prognosis in Gastric Cancer With Intestinal Phenotype," J. Surg. Oncol., October 25, 2006, [Epub ahead of print].	
CB	CE1	Zeher et al., "Fibrinolysis-Resistant Fibrin Deposits in Minor Labial Salivary Glands of Patients with Sjogren's Syndrome," Clinical Immunology and Immunopathology 71(2):149-155 (1994)	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature	Christina Borgeest	Date Considered	8/2/07
--------------------	--------------------	-----------------	--------